ClinicalTrials.gg
CompletedNCT06697717Updated Sep 2, 2026

End-expiratory Transpulmonary Pressure-guided vs Electrical Impedance Tomography-guided PEEP Titration Methods in Patients With Intra-abdominal Hypertension Combined With Acute Respiratory Distress Syndrome: a Randomized Crossover Controlled Study

An interventional study of Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients and EIT-Guided PEEP Titration in IAH and ARDS Patients in Intra-abdominal Hypertension and Acute Respiratory Distress Syndrome (ARDS), sponsored by XiaoJing Zou,MD. Completed at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by XiaoJing Zou,MD · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

This study aims to adopt a randomized crossover design to compare the effects of end-expiratory transpulmonary pressure-guided PEEP titration and EIT-guided PEEP titration on local lung ventilation, shunt, dead space, and ventilation-perfusion (V/Q) ratio as monitored by EIT. Additionally, it will evaluate their impact on respiratory mechanics, chest wall mechanics, mechanical power, hemodynamics, gas exchange, intra-abdominal pressure. By identifying an optimal PEEP titration strategy for patients with intra-abdominal hypertension (IAH) and acute respiratory distress syndrome (ARDS), this study aims to develop a mechanical ventilation approach that maintains lung recruitment and minimizes lung injury while avoiding adverse effects on other organs. The findings could facilitate the clinical application of this strategy and benefit a broader population of patients with IAH and ARDS.

02

Conditions studied

  • Intra-abdominal Hypertension
  • Acute Respiratory Distress Syndrome (ARDS)
03

In context

Intra-Abdominal Hypertension

71 studies on the registry are indexed under Intra-Abdominal Hypertension; 16 are open to participants now.

This study's enrollment of 15 is below the median of 60 across 32 interventional studies indexed under Intra-Abdominal Hypertension.

Browse Intra-Abdominal Hypertension studies →

Lead sponsor

XiaoJing Zou,MD is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age: 18-80 years;
  2. meets IAH ≥12 mmHg;
  3. meets the diagnostic criteria of the Berlin definition of ARDS;
  4. PaO2/FiO2 ≤ 200;
  5. within 36 hours of invasive mechanical ventilation;
  6. patients or their family members were consulted, agreed to participate in the trial, and signed an form.

Exclusion criteria

Exclusion Criteria:

  1. Age \<18 years or age >80 years;
  2. uncorrected shock of any type;
  3. , interstitial lung disease, pulmonary embolism, right heart failure, pulmonary hypertension, or severe cardiac arrhythmia;
  4. pneumothorax or bronchopleural fistula or lobectomy or other surgery of the lungs within 2 weeks of surgery;
  5. non-invasive ventilation or transnasal high-flow oxygen;
  6. with relevant to the application of EIT (large chest skin injuries, infections, pacemaker implanters, in vivo automatic defibrillator implantation, etc.) pneumothorax, mediastinal emphysema, massive pleural effusion;
  7. oesophageal obstruction, oesophageal perforation, severe oesophageal variceal bleeding, upper gastrointestinal surgery, and other factors that make it impossible to place an oesophageal pressure catheter;
  8. diaphragmatic hernia, thoracic deformity; patients with obvious pulmonary hernias;
  9. prolongation of (PT), activated partial thromboplastin time (APTT) to two times the high limit of normal values or with active bleeding in the nasopharynx;
  10. severe neurological disease: intracranial hypertension or neuromuscular disease, etc;
  11. pregnant and lactating women;
  12. patients to be treated with ECMO;
  13. re-admission to the ICU of patients who have already been included in this study, or who are participating in other clinical studies;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
15 participants (actual)

Study arms

  • Experimental
    Transpulmonary Pressure-Guided PEEP Titration

    Other: Transpulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients

  • Experimental
    EIT-Guided PEEP Titration

    Other: EIT-Guided PEEP Titration in IAH and ARDS Patients

Interventions

  • OtherTranspulmonary Pressure-Guided PEEP Titration in IAH and ARDS Patients

    After completion of baseline ventilation and lung recruitment, the ventilator was switched to volume-controlled mode, and PEEP was set using an empirical PL-FiO₂ table, with the goal of maintaining end-expiratory transpulmonary pressure (PL) \> 0 cmH₂O and end-inspiratory PL ≤ 20 cmH₂O.

  • OtherEIT-Guided PEEP Titration in IAH and ARDS Patients

    After completion of baseline ventilation and lung recruitment, the ventilator was switched to pressure-controlled mode with a pressure control (PC) of 15 cmH₂O. PEEP was initially set at 24 cmH₂O and then gradually decreased in steps of 3 cmH₂O, with each PEEP level maintained for 2 minutes, down to a minimum of 3 cmH₂O, using the ODCL method for PEEP titration.

06

What researchers measure

Primary outcomes

  1. Difference between the optimal PEEP titrated based on end-expiratory transpulmonary pressure and that guided by EIT

    Time frame: After PEEP titration

Secondary outcomes

  1. Electrical impedance tomography (EIT) parameters included: Global inhomogeneity (GI) index、Center of ventilation (CoV)、Shunt fraction、V/Q matching ,and so on

    Time frame: 30-minute ventilation after PEEP titration

  2. Clinical respiratory and hemodynamic parameters

    Time frame: 30-minute ventilation after PEEP titration

07

Study locations

1 site
  • Wuhan Union Hospital
    Wuhan, Hubei, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2024 to primary completion in Feb 2026, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2024
First posted
Nov 20, 2024
StartActual
Dec 31, 2024
Primary completionActual
Feb 20, 2026
CompletionActual
Feb 20, 2026
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06697717
Lead sponsor
XiaoJing Zou,MD
Responsible party
XiaoJing Zou,MD (Clinical Professor, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology) — Sponsor-investigator
First posted
Nov 20, 2024
Start date
Dec 31, 2024
Primary completion
Feb 20, 2026
Completion
Feb 20, 2026
Last update
Sep 2, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion